Dr. Tang has long been engaged in efficiently discovering and optimizing functional small molecules by drug design and medicinal chemistry, exploring the molecular mechanism of action by target identification and validation, as well as improving the drug-like properties of drug candidates and examining their therapeutic potential in disease models, with a focus on the research topics of cancer, metabolic diseases and regenerative medicine.  

2002-2006	B.S. in Chemistry, Department of Chemistry, Jilin   University, Changchun, China Advisor: Prof. Ying Mu
2006-2011	Ph.D. in Organic Chemistry,  School of Chemistry and Chemical Engineering and   State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou, China Advisor: Prof.   Xuegong She Research areas: Development of synthetic methodology   and total   synthesis of   bioactive natural products

2011-2017	Postdoctoral  Fellow, Gladstone Institutes, University of California,  San Francisco, San   Francisco, USA Advisor: Prof.  Sheng Ding  Research areas: Synthesis  and discovery of   novel small molecules that control   cell fates and functions, and examining their therapeutic  potential in disease models
2017-present	Group leader, Guangzhou Institutes of  Biomedicine and Health, Chinese Academy of Science, Guangzhou, China Research areas: Discovery and  preclinical development of small-molecule drugs for the treatment of aging realted diseases, e.g., cancer, metabolic diseases, etc.

   

24. Wu T^#, Li ST^#, Ran Y^#, Lin Y, Liu L, Zhang X, Zhou L, Zhang L, Wu D, Yang B^*, Tang S^*. Mapping protein direct interactome of oxidoreductases with small molecular chemical cross-linkers in live cells. Redox Biol. 2023 May;61:102642.

23. Shi R, Shi X, Qin D, Tang S, Vermeulen M, Zhang X. SNX27-driven membrane localisation of OTULIN antagonises linear ubiquitination and NF-κB signalling activation. Cell Biosci. 2021 Jul 27;11(1):146. PMID: 34315543

22. Liu X, Zhang Y, Chu Y, Zhao X, Mao L, Zhao S, Lin S, Hui X, Gu P, Xu Y, Loomes K, Tang S^*, Nie T^*, Wu D^*. The natural compound rutaecarpine promotes white adipocyte browning through activation of the AMPK-PRDM16 axis. Biochem Biophys Res Commun. 2021;545:189-194. PMID: 33561654 

21. Tan J, Liu H, Huang M, Li N, Tang S, Meng J, Tang S, Zhou H, Kijlstra A, Yang P, Hou S. Small molecules targeting RORγt inhibit autoimmune disease by suppressing Th17 cell differentiation. Cell Death Dis. 2020 Aug 22;11(8):697. PMID: 32829384 

20. Zhao S, Chu Y, Zhang Y, Zhou Y, Jiang Z, Wang Z, Mao L, Li K, Sun W, Li P, Jia S, Wang C, Xu A, Loomes K, Tang S, Wu D, Hui X, Nie T.Linifanib exerts dual anti-obesity effect by regulating adipocyte browning and formation. Life Sci. 2019 Apr 1;222:117-124. PMID: 30708100 

19. Sun W, Zhao X, Wang Z, Chu Y, Mao L, Lin S, Gao X, Song Y, Hui X, Jia S, Tang S, Xu Y, Xu A, Loomes K, Wang C, Wu D, Nie T. Tbx15 is required for adipocyte browning induced by adrenergic signaling pathway. Mol Metab. 2019 Oct;28:48-57. PMID: 31352005

18. Hou L^#, Yang G^#, Tang S^#, Alcazar C, Joshi P, Strassberg Z, Kim M, Kawamura M, Woo YJ, Shrager J, Ding S, Huang NF. A small molecule derived from carboxyethylpyrrole protein adducts promotes angiogenesis in a mouse model of peripheral arterial disease. J Am Heart Assoc. 2018 Sep 18;7(18):e009234. PMID: 30371212 (^#equal contribution)

17. Qin Y^#, Tang S^#, Zhen G, Ding Q, Ding S, Cao X. Bone-targeted delivery of TGF-β type 1 receptor inhibitor rescues uncoupled bone remodeling in Camurati-Engelmann disease. Ann N Y Acad Sci. 2018 Dec; 1433(1):29-40. PMID: 30091466 (^#equal contribution)

16. Yang B^#, Tang S^#, Ma C^#, Li ST, Shang GC, Dang B, DeGrado WF, Dong MQ, Wang PG, Ding S, Wang L. Spontaneous and specific chemical cross-linking in live cells to capture and identify protein interactions. Nat Commun. 2017 Dec 21;8(1):2240. PMID: 29269770 (^#equal contribution)

15. Xie M^#, Tang S^#, Li K, Ding S. Pharmacological reprogramming of somatic cells for regenerative medicine. Acc Chem Res. 2017 May 16; 50(5):1202-1211. PMID: 28453285. (^#equal contribution)

14. Mohamed TMA, Stone NR, Berry EC, Radzinsky E, Huang Y, Pratt K, Ang Y, Yu P, Wang H, Tang S, Magnitsky S, Ding S, Ivey KN, Srivastava D. Chemical enhancement of in vitro and in vivo direct cardiac reprogramming. Circulation. 2017 Mar 7; 135(10):978-995. PMID: 27834668. (a number of major media reports, including ABC 7, Fierce Biotech, Daily Mail, etc.)

13. Nie B, Nie T, Hui X, Gu P, Mao L, Li K, Yuan R, Zheng J, Wang H, Li K, Tang S, Zhang Y, Xu T, Xu A, Wu D, Ding S. Brown adipogenic reprogramming induced by a small molecule. Cell Rep. 2017 Jan 17;18(3):624-635. PMID: 28099842. 

12. Nakamura PA, Shimchuk AA, Tang S, Wang Z, Degolier K, Ding S, Reh TA. Small molecule Photoregulin3 prevents retinal degeneration in the Rho^P23H mouse model of Retinitis Pigmentosa. eLife 2017 Nov 17; 6. pii: e30577. PMID: 29148976. 

11. Nakamura PA, Tang S, Shimchuk AA, Ding S, Reh TA. Potential of small molecule-mediated reprogramming of rod photoreceptors to treat retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2016 Nov 1; 57(14):6407-6415. PMID: 27893103. (reported by Foundation Fighting Blindness)

10. Tang S^#, Xie M^#, Cao N, Ding S. Patient-specific induced pluripotent stem cells for disease modeling and phenotypic drug discovery. J Med Chem. 2016 Jan 14; 59(1):2-15. PMID: 26322868. (^#equal contribution)

9. Zhu S, Russ HA, Wang X, Zhang M, Ma T, Xu T, Tang S, Hebrok M, Ding S. Human pancreatic beta-like cells converted from fibroblasts. Nat Commun. 2016 Jan 6; 7:10080. PMID: 26733021. (a number of major media reports, including Fox News, The Independent, SF Business Times, etc.)

8. Yu C^#, Liu K^#, Tang S^#, Ding S. Chemical approaches to cell reprogramming. Curr Opin Genet Dev. 2014 Oct; 28:50-6. PMID: 25461450. (^#equal contribution)

7. Dai Q, Xie X, Xu S, Ma D, Tang S, She X. Total syntheses of Tardioxopiperazine A, Isoechinulin A, and Variecolorin C. Org Lett. 2011 May 6; 13(9):2302-5. PMID: 21456528. 

6. Tang S, Xie X, Wang X, He L, Xu K, She X. Concise total syntheses of (+)-strictifolione and (6R)-6-[(4R,6R)-4,6-dihydroxy-10-phenyldec-1-enyl]-5,6-dihydro-2H-pyran-2-one. J Org Chem. 2010 Dec 3; 75(23):8234-40. PMID: 21067232.

5. Sun Y, Yu B, Wang X, Tang S, She X, Pan X. Stereoselective syntheses of four diastereomers of 3,9,12-trihydroxycalamenene via a benzobicyclo[3.3.1] intermediate. J Org Chem. 2010 Jun 18; 75(12):4224-9. PMID: 20481593. 

4. Wang W, Zhang J, He J, Tang S, Wang X, She X, Pan X. Asymmetric total synthesis of (-)-Cladospolide B. Chin J Chem. 2008, 26(6), 1109-1113. 

3. Tang S, He J, Sun Y, He L, She X. Efficient and regioselective synthesis of 5-hydroxy-2-isoxazolines: versatile synthons for isoxazoles, beta-lactams, and gamma-amino alcohols. J Org Chem. 2010 Mar 19; 75(6):1961-6. PMID: 20151710. 

2. He J, Tang S, Tang S, Liu J, Sun Y, Pan X, She X. Assembly of functionalized α-hydroxy carbonyl compounds via combination of N-heterocyclic carbene and Pd catalysts. Tetrahedron Lett. 2009, 50 (4), 430-433.

1. Tang S, He J, Sun Y, He L, She X. Efficient and regioselective one-pot synthesis of 3-substituted and 3,5-disubstituted isoxazoles. Org Lett. 2009 Sep 3; 11(17):3982-5. PMID: 19708706. (highlighted by scientific journal SynFacts)

3. 一种小分子化学交联剂及其制备方法和应用, Application number: 202310163905X, Application date: 2023/02/24, Inventors: TANG Shibing; YANG Bing; WU Ting, Application country: China.

2. DNMT1 inhibitors, pharmaceutical compositions, and therapeutic applications, Application number: PCT/CN2023/073678, Application date: 2023/01/29, Inventors: TANG Shibing; KONG Xiangqian; LUO Cheng; ZHAO Kehao; LI Zhihai, Application country: PCT patent.

1. Photoreceptor gene modulator photoregulin 3 for treatment of retinal disease, Application number: PCT/US2018/046272 (WO2019032999), Application date: 2018/08/10, Inventors: REH Thomas A.; NAKAMURA Paul; SHIMCHUK Andy; TANG Shibing; DING Sheng, Application country: PCT patent.

Medicinal chemistry, Drug discovery, Chemical biology, Regenerative medicine.